Grünenthal is a global leader in pain management.

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.

Katrin Fleischer, Global Regulatory Strategy
Sabine Hess, Technician Cellular & Molecular Biology
Andrew Lockhart, Head Translational and Disease Understanding Unit
Loi Vo, National Market Access Manager
Our Vision: A World Free of Pain

Grünenthal Stories

100 Reasons for a World Free of Pain - Álvaro Rodríguez
100 Reasons for a World Free of Pain – Álvaro Rodríguez

Álvaro Rodríguez can feel the deep trust when he visits healthcare professionals to discuss optimal approaches to pain management. In this short interview, he shares his real-world experiences of making a positive impact on patients’ lives.

100 Reasons for a World Free of Pain - Sandra Ventura & Vasco Lobo
100 Reasons for a World Free of Pain - Sandra Ventura & Vasco Lobo

Relieving chronic pain is the focus of our daily work – and it affects many Grünenthal employees in their personal lives too. In this short interview, Sandra Ventura and Vasco Lobo explain how personal experiences of chronic pain inspire their professional life.

⁠MSCI recognises Grünenthal as an ESG industry leader
MSCI awards Provisional AA score in ESG rating 

Grünenthal is taking action to maximise its contribution to people’s lives and minimise its environmental impact. An external assessment from MSCI recognises our industry-leading approach to these topics by awarding our company a Provisional AA rating.

Diabetes and Pain: A Focus on Polyneuropathy on World Diabetes Day
Diabetes and pain: a focus on polyneuropathy on World Diabetes Day

Today is World Diabetes Day, which reminds us of the widespread nature of diabetes and the health challenges that those affected must overcome.

20 countries certified Great Place to Work®
Record-high results and more entities certified in 2024 Great Place to Work® survey

More than 3,700 Grünenthal employees gave feedback during the global Great Place to Work® survey in 2024. 83% of them consider Grünenthal a great place to work. In addition, 20 of our operating countries were certified as a Great Place to Work.

World Arthritis Day
Karen’s story: Living with osteoarthritis of the knees

Our Grünenthal colleague Karen shares her experience of living with osteoarthritis in her knee.

NOP First-In-Human-Trial Announcement Grünenthal

First participants enrolled in Phase I NOP trial

Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025.
Get more insides in our press release
Grünenthal Annual Report 2023/24 (Grünenthal Scientific Body & Grünenthal Report Cover Image)

Annual Report 2023/24

4,400 Grünenthal employees worldwide join forces every day to drive progress towards our vision of a World Free of Pain. Together, we achieved record revenues in 2023. And our scientists made important progress with developing innovative medicines for pain patients.

Our most recent report shares information about our company’s strategy, highlight projects and financial performance.

Check out the Grünenthal Report.
Grünenthal Responsibility

Responsibility Report 2023

Grünenthal’s strategy and culture are closely tied to its deep commitment to conducting business responsibly. We aim to have a net-positive impact on patients, employees, partners, and wider society. Each year, we publish our progress in a detailed and externally audited report – in line with the Global Reporting Initiative (GRI) standards.
Check out our latest Responsibility Report.
Job Portal - Tout Primary 1800x759px

Careers

Working at Grünenthal means experiencing the impact you can have on the results we achieve and the lives of the patients we serve.

Join forces.

Make an impact.

Innovate for a world free of pain.


Visit our careers website
Great Place to Work® Certified DE, AT, CH, DK  SEP 2024 -SEP 2025
Great Place to Work® Certified BE, NL, IE, UK SEP 2024 -SEP 2025
Great Place to Work® Certified IT, ES, P,T FR SEP 2024 -SEP 2025
Great Place to Work® Certified EC, MX, CL, PE SEP 2024 -SEP 2025
Great Place to Work® Certified PA, CO, BR, US SEP 2024 -SEP 2025
Sustainalytics Logo